Form 8-K - Current report:
SEC Accession No. 0001140361-24-037974
Filing Date
2024-08-21
Accepted
2024-08-20 20:16:44
Documents
15
Period of Report
2024-08-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20034419_8k.htm   iXBRL 8-K 32448
2 EXHIBIT 10.1 ef20034419_ex10-1.htm EX-10.1 501147
3 EXHIBIT 10.2 ef20034419_ex10-2.htm EX-10.2 676024
  Complete submission text file 0001140361-24-037974.txt   1578662

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA bbio-20240816.xsd EX-101.SCH 3868
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20240816_lab.xml EX-101.LAB 21966
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20240816_pre.xml EX-101.PRE 16046
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20034419_8k_htm.xml XML 4225
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 241226900
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)